Loading...
Loading...
Also known as: Ozempic, Wegovy, Rybelsus, GLP-1 RA
An FDA-approved GLP-1 receptor agonist originally developed for type 2 diabetes, now widely used for weight management and metabolic optimization.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has revolutionized the treatment of obesity and type 2 diabetes. It mimics the incretin hormone GLP-1, which regulates appetite, blood sugar, and metabolic function.
The STEP clinical trial program demonstrated that semaglutide 2.4mg weekly produced average weight loss of 14.9% over 68 weeks. The SELECT trial showed a 20% reduction in major cardiovascular events.
Semaglutide activates GLP-1 receptors in the pancreas (increasing insulin secretion), gut (slowing gastric emptying), and brain (reducing appetite via hypothalamic signaling). Its albumin-binding fatty acid side chain extends half-life to ~7 days.
Typical Dose
0.25-2.4mg
Frequency
Weekly
Cycle Length
Ongoing (chronic use)
Half-Life
~7 days
FDA-approved. Extensive Phase III clinical trial data (STEP, SUSTAIN, SELECT programs). Post-marketing surveillance ongoing.
Common: nausea, vomiting, diarrhea (usually transient). Rare: pancreatitis, gallbladder events. Contraindicated in personal/family history of medullary thyroid carcinoma or MEN2. Do not use during pregnancy.
A 15-amino-acid peptide derived from human gastric juice with potent tissue-healing and anti-inflammatory properties.
Fertility Preservation: Maintains testosterone and spermatogenesis during TRT.
Potential Benefits: Increases in lean body mass, reductions in adipose tissue, improved metabolic parameters.